News und Analysen

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

An SEC filing dated

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of

Graphene Investments SAS fully exited its position in Centene Corporation (NYSE:CNC) during the third quarter, selling approximately 55,600 shares in a transaction estimated at ~$3.02 million as of

On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (NASDAQ:INCY), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this

On October 10, 2025, Sarasin & Partners LLP disclosed a significant reduction in its UnitedHealth Group (NYSE:UNH) stake, selling 465,744 shares in an estimated $140.86 million trade.

Sarasin &amp

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining

The 6.7% dividend yield on offer from Pfizer (NYSE: PFE) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable. But

UnitedHealth (NYSE: UNH) shares are up significantly since I upgraded the stock to a buy rating.

*Stock prices used were the afternoon prices of Oct. 6, 2025. The video was published on Oct. 8

There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer

Shares in Viking Therapeutics (NASDAQ: VKTX) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.

According to a filing

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices

Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications

Shares of America's largest health insurer, UnitedHealth Group, have been on a relatively wild ride. After hitting a peak in April, the stock fell by more than half.

Shares of UnitedHealth Group

Pfizer (NYSE: PFE) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news. But Pfizer's price rebound

If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many

According to an SEC filing dated October 2, 2025, St. Louis Financial Planners Asset Management, LLC initiated a new stake in UnitedHealth Group (NYSE:UNH), purchasing 12,542 shares during the third

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products.

*Stock prices used were the afternoon prices of Oct. 3, 2025. The video was published on Oct. 5

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good

Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.

It has developed many medicines over the years

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (NASDAQ: AMGN) started the year